{"id":"https://openalex.org/W7204187118","doi":"https://doi.org/10.1080/1750743x.2026.2722556","title":"Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report","display_name":"Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report","publication_year":2026,"publication_date":"2026-08-25","ids":{"openalex":"https://openalex.org/W7204187118","doi":"https://doi.org/10.1080/1750743x.2026.2722556","pmid":"https://pubmed.ncbi.nlm.nih.gov/42639811"},"language":"en","primary_location":{"id":"doi:10.1080/1750743x.2026.2722556","doi":"https://doi.org/10.1080/1750743x.2026.2722556","is_oa":false,"landing_page_url":"https://doi.org/10.1080/1750743x.2026.2722556","pdf_url":null,"source":{"id":"https://openalex.org/S71887004","display_name":"Immunotherapy","issn_l":"1750-743X","issn":["1750-743X","1750-7448"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5148134471","display_name":"Zhiqiang Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183519381","display_name":"Capital Medical University","ror":"https://ror.org/013xs5b60","country_code":"CN","type":"education","lineage":["https://openalex.org/I183519381"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhiqiang Li","raw_affiliation_strings":["Capital Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Capital Medical University","institution_ids":["https://openalex.org/I183519381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011894904","display_name":"Yufei Li","orcid":"https://orcid.org/0009-0007-6031-4860","observed_orcids":["https://orcid.org/0009-0007-6031-4860"]},"institutions":[{"id":"https://openalex.org/I4210124809","display_name":"Peking University People's Hospital","ror":"https://ror.org/035adwg89","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210124809"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yufei Li","raw_affiliation_strings":["Peking University People\u2019s Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peking University People\u2019s Hospital","institution_ids":["https://openalex.org/I4210124809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100385419","display_name":"Yuhan Zhang","orcid":"https://orcid.org/0000-0002-2768-3900","observed_orcids":["https://orcid.org/0000-0002-2768-3900"]},"institutions":[{"id":"https://openalex.org/I183519381","display_name":"Capital Medical University","ror":"https://ror.org/013xs5b60","country_code":"CN","type":"education","lineage":["https://openalex.org/I183519381"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yuhan Zhang","raw_affiliation_strings":["Capital Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Capital Medical University","institution_ids":["https://openalex.org/I183519381"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Qiuxia Ye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124809","display_name":"Peking University People's Hospital","ror":"https://ror.org/035adwg89","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210124809"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Qiuxia Ye","raw_affiliation_strings":["Peking University People\u2019s Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peking University People\u2019s Hospital","institution_ids":["https://openalex.org/I4210124809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5133711892","display_name":"Jing He","orcid":"https://orcid.org/0000-0003-3904-8928","observed_orcids":["https://orcid.org/0000-0003-3904-8928"]},"institutions":[{"id":"https://openalex.org/I4210124809","display_name":"Peking University People's Hospital","ror":"https://ror.org/035adwg89","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210124809"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jing He","raw_affiliation_strings":["Peking University People\u2019s Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peking University People\u2019s Hospital","institution_ids":["https://openalex.org/I4210124809"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100425354","display_name":"Mingwei Li","orcid":"https://orcid.org/0000-0002-0912-3408","observed_orcids":["https://orcid.org/0000-0002-0912-3408"]},"institutions":[{"id":"https://openalex.org/I183519381","display_name":"Capital Medical University","ror":"https://ror.org/013xs5b60","country_code":"CN","type":"education","lineage":["https://openalex.org/I183519381"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Mingwei Li","raw_affiliation_strings":["Capital Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Capital Medical University","institution_ids":["https://openalex.org/I183519381"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5100425354"],"corresponding_institution_ids":["https://openalex.org/I183519381"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.64180538,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"1","last_page":"7"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/low-dose-il-2","display_name":"low-dose interleukin-2","score":0.9639999866485596},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":1.0},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9490000009536743},{"id":"https://openalex.org/keywords/cutaneous-adverse-effects","display_name":"cutaneous adverse events","score":0.7519999742507935},{"id":"https://openalex.org/keywords/pd-1-ctla-4-bispecific-antibody","display_name":"PD-1/CTLA-4 bispecific antibody","score":0.9269999861717224},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8809999823570251},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.925000011920929},{"id":"https://openalex.org/keywords/erythema","display_name":"erythema","score":0.6269999742507935},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.9900000095367432},{"id":"https://openalex.org/keywords/corticosteroids","display_name":"corticosteroids","score":0.8339999914169312},{"id":"https://openalex.org/keywords/immunomodulatory-therapy","display_name":"immunomodulatory therapy","score":0.7879999876022339}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8841000199317932},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7376999855041504},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.7193999886512756},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5059000253677368},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.46709999442100525},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4388999938964844},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4302000105381012},{"id":"https://openalex.org/C2779121184","wikidata":"https://www.wikidata.org/wiki/Q1166142","display_name":"Erythema","level":2,"score":0.42100000381469727},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40130001306533813},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39959999918937683},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38670000433921814},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.35519999265670776},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.35510000586509705},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3199999928474426},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.30630001425743103},{"id":"https://openalex.org/C21705690","wikidata":"https://www.wikidata.org/wiki/Q2907609","display_name":"CTLA-4","level":4,"score":0.3050999939441681},{"id":"https://openalex.org/C2777789703","wikidata":"https://www.wikidata.org/wiki/Q192102","display_name":"Skin cancer","level":3,"score":0.2955000102519989},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.29260000586509705},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2800000011920929},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.27709999680519104},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.2630999982357025},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.26179999113082886}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1080/1750743x.2026.2722556","doi":"https://doi.org/10.1080/1750743x.2026.2722556","is_oa":false,"landing_page_url":"https://doi.org/10.1080/1750743x.2026.2722556","pdf_url":null,"source":{"id":"https://openalex.org/S71887004","display_name":"Immunotherapy","issn_l":"1750-743X","issn":["1750-743X","1750-7448"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunotherapy","raw_type":"journal-article"},{"id":"pmid:42639811","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42639811","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7777485847473145,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W1967884480","https://openalex.org/W2079120231","https://openalex.org/W2099958672","https://openalex.org/W2102031533","https://openalex.org/W2106107076","https://openalex.org/W2118075045","https://openalex.org/W2148494144","https://openalex.org/W2477823035","https://openalex.org/W2593117122","https://openalex.org/W2830145191","https://openalex.org/W2901041673","https://openalex.org/W2911882091","https://openalex.org/W2943769232","https://openalex.org/W2952065098","https://openalex.org/W2970258718","https://openalex.org/W2973404796","https://openalex.org/W2980907934","https://openalex.org/W2982218448","https://openalex.org/W3010505906","https://openalex.org/W3014279612","https://openalex.org/W3014340654","https://openalex.org/W3036371943","https://openalex.org/W3040373516","https://openalex.org/W3045735122","https://openalex.org/W3096185164","https://openalex.org/W3118904262","https://openalex.org/W3129588953","https://openalex.org/W3163284774","https://openalex.org/W3184010944","https://openalex.org/W4205454439","https://openalex.org/W4210429334","https://openalex.org/W4220996377","https://openalex.org/W4297497772","https://openalex.org/W4297497801","https://openalex.org/W4308514773","https://openalex.org/W4308861908","https://openalex.org/W4314937969","https://openalex.org/W4315871770","https://openalex.org/W4367291634","https://openalex.org/W4375860868","https://openalex.org/W4400332207","https://openalex.org/W4403632059","https://openalex.org/W4407187064","https://openalex.org/W4408282309"],"related_works":[],"abstract_inverted_index":{"Immune":[0],"checkpoint":[1],"inhibitors":[2],"(ICIs),":[3],"including":[4],"novel":[5],"bispecific":[6],"antibodies":[7],"targeting":[8],"programmed":[9],"cell":[10],"death":[11],"protein":[12,18],"1":[13],"(PD-1)":[14],"and":[15,31,81,87,96,100,129,140],"cytotoxic":[16],"T-lymphocyte-associated":[17],"4":[19],"(CTLA-4),":[20],"have":[21,26],"expanded":[22],"therapeutic":[23],"options":[24],"but":[25],"also":[27],"increased":[28],"the":[29,68,120,134,141,156,164],"incidence":[30],"complexity":[32],"of":[33,70,119,137,159,166],"immune-related":[34],"adverse":[35,168],"events":[36],"(irAEs).":[37],"Low-dose":[38],"interleukin-2":[39],"(Ld-IL2)":[40],"has":[41],"been":[42],"explored":[43],"as":[44],"a":[45,71],"potential":[46,157],"immunomodulatory":[47],"strategy.":[48],"However,":[49,149],"its":[50],"role":[51],"in":[52,163],"real-world":[53],"combination":[54],"regimens":[55],"for":[56],"managing":[57],"severe":[58],"cutaneous":[59],"irAEs":[60],"remains":[61],"to":[62,154],"be":[63,147],"fully":[64],"elucidated.":[65],"We":[66],"report":[67],"case":[69],"patient":[72],"with":[73,85,116],"gastric":[74],"cancer":[75],"who":[76],"developed":[77],"rapidly":[78],"progressive":[79],"erythema":[80],"pruritus":[82],"after":[83],"treatment":[84,106,139],"iparomlimab":[86],"tuvonralimab.":[88],"Symptoms":[89],"worsened":[90],"despite":[91],"corticosteroids,":[92],"intravenous":[93],"immunoglobulin":[94],"(IVIG)":[95],"antihistamines.":[97],"After":[98],"Ld-IL2":[99],"thalidomide":[101],"were":[102,131],"added":[103],"while":[104],"corticosteroid":[105],"was":[107,111],"continued,":[108],"clinical":[109],"improvement":[110],"observed":[112],"within":[113],"48":[114],"hours,":[115],"complete":[117],"resolution":[118],"skin":[121],"lesions":[122],"at":[123],"2":[124],"weeks.":[125],"Because":[126],"Ld-IL2,":[127],"thalidomide,":[128],"corticosteroids":[130],"administered":[132],"concurrently,":[133],"independent":[135],"contribution":[136],"each":[138],"underlying":[142],"immunological":[143],"mechanism":[144],"could":[145],"not":[146],"determined.":[148],"further":[150],"studies":[151],"are":[152],"warranted":[153],"clarify":[155],"value":[158],"this":[160],"combined":[161],"regimen":[162],"management":[165],"such":[167],"events.":[169]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2026-08-26T00:00:00"}